Search Results - "Cancer science"

Reactive oxygen species in cancer: Current findings and future directions by Nakamura, Hajime, Takada, Kohichi

“…Reactive oxygen species (ROS), a class of highly bioactive molecules, have been widely studied in various types of cancers. ROS are considered to be normal…”
Get full text

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? by Ohue, Yoshihiro, Nishikawa, Hiroyoshi

“…Regulatory T (Treg) cells suppress abnormal/excessive immune responses to self‐ and nonself‐antigens to maintain immune homeostasis. In tumor immunity, Treg…”
Get full text

5‐Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes by Blondy, Sabrina, David, Valentin, Verdier, Mireille, Mathonnet, Muriel, Perraud, Aurélie, Christou, Niki

“…Colorectal cancer (CRC) is a public health problem. It is the third most common cancer in the world, with nearly 1.8 million new cases diagnosed in 2018. The…”
Get full text

Emerging roles of long non‐coding RNA in cancer by Sanchez Calle, Anna, Kawamura, Yumi, Yamamoto, Yusuke, Takeshita, Fumitaka, Ochiya, Takahiro

“…Since comprehensive analysis of the mammalian genome revealed that the majority of genomic products are transcribed in long non‐coding RNA (lncRNA), increasing…”
Get full text

Tumor microenvironment in gastric cancers by Oya, Yukiko, Hayakawa, Yoku, Koike, Kazuhiko

“…The tumor microenvironment favors the growth and expansion of cancer cells. Many cell types are involved in the tumor microenvironment such as inflammatory…”
Get full text

Targeted exosome‐encapsulated erastin induced ferroptosis in triple negative breast cancer cells by Yu, Mengyu, Gai, Chengcheng, Li, Zihaoran, Ding, Dejun, Zheng, Jie, Zhang, Weifen, Lv, Shijun, Li, Wentong

“…Ferroptosis is an iron‐dependent, lipid peroxide‐driven cell death caused by inhibition of the cystine/glutamate transporter, which is of importance for the…”
Get full text

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study by Sunami, Kuniko, Ichikawa, Hitoshi, Kubo, Takashi, Kato, Mamoru, Fujiwara, Yutaka, Shimomura, Akihiko, Koyama, Takafumi, Kakishima, Hiroki, Kitami, Mayuko, Matsushita, Hiromichi, Furukawa, Eisaku, Narushima, Daichi, Nagai, Momoko, Taniguchi, Hirokazu, Motoi, Noriko, Sekine, Shigeki, Maeshima, Akiko, Mori, Taisuke, Watanabe, Reiko, Yoshida, Masayuki, Yoshida, Akihiko, Yoshida, Hiroshi, Satomi, Kaishi, Sukeda, Aoi, Hashimoto, Taiki, Shimizu, Toshio, Iwasa, Satoru, Yonemori, Kan, Kato, Ken, Morizane, Chigusa, Ogawa, Chitose, Tanabe, Noriko, Sugano, Kokichi, Hiraoka, Nobuyoshi, Tamura, Kenji, Yoshida, Teruhiko, Fujiwara, Yasuhiro, Ochiai, Atsushi, Yamamoto, Noboru, Kohno, Takashi

“…Next‐generation sequencing (NGS) of tumor tissue (ie, clinical sequencing) can guide clinical management by providing information about actionable gene…”
Get full text

Oncolytic virus therapy: A new era of cancer treatment at dawn by Fukuhara, Hiroshi, Ino, Yasushi, Todo, Tomoki

“…Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success in immunotherapy using immune checkpoint inhibitors…”
Get full text

Exosomes in cancer development and clinical applications by Tai, Yu‐Ling, Chen, Ko‐Chien, Hsieh, Jer‐Tsong, Shen, Tang‐Long

“…Exosomes participate in cancer progression and metastasis by transferring bioactive molecules between cancer and various cells in the local and distant…”
Get full text

Immune infiltration in renal cell carcinoma by Zhang, Shichao, Zhang, Erdong, Long, Jinhua, Hu, Zuquan, Peng, Jian, Liu, Lina, Tang, Fuzhou, Li, Long, Ouyang, Yan, Zeng, Zhu

“…Immune infiltration of tumors is closely associated with clinical outcome in renal cell carcinoma (RCC). Tumor‐infiltrating immune cells (TIICs) regulate…”
Get full text

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma by Baba, Yoshifumi, Nomoto, Daichi, Okadome, Kazuo, Ishimoto, Takatsugu, Iwatsuki, Masaaki, Miyamoto, Yuji, Yoshida, Naoya, Baba, Hideo

“…Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer, predominantly constituting 90% of cases worldwide…”
Get full text

Lipoxygenase‐mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3 by Shintoku, Ryosuke, Takigawa, Yuta, Yamada, Keiichi, Kubota, Chisato, Yoshimoto, Yuhei, Takeuchi, Toshiyuki, Koshiishi, Ichiro, Torii, Seiji

“…In cancer cells the small compounds erastin and RSL3 promote a novel type of cell death called ferroptosis, which requires iron‐dependent accumulation of lipid…”
Get full text

Pyroptosis, a new bridge to tumor immunity by Li, Lisha, Jiang, Mingxia, Qi, Ling, Wu, Yiming, Song, Dongfeng, Gan, Junqing, Li, Yanjing, Bai, Yuxian

“…Pyroptosis refers to the process of gasdermin (GSDM)‐mediated programmed cell death (PCD). Our understanding of pyroptosis has expanded beyond cells and is…”
Get full text

Tumor‐derived spheroids: Relevance to cancer stem cells and clinical applications by Ishiguro, Tatsuya, Ohata, Hirokazu, Sato, Ai, Yamawaki, Kaoru, Enomoto, Takayuki, Okamoto, Koji

“…Recently, many types of in vitro 3‐D culture systems have been developed to recapitulate the in vivo growth conditions of cancer. The cancer 3‐D culture…”
Get full text

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model by Kimura, Takayuki, Kato, Yu, Ozawa, Yoichi, Kodama, Kotaro, Ito, Junichi, Ichikawa, Kenji, Yamada, Kazuhiko, Hori, Yusaku, Tabata, Kimiyo, Takase, Kazuma, Matsui, Junji, Funahashi, Yasuhiro, Nomoto, Kenichi

“…Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against…”
Get full text

Biology and therapeutic potential of mesenchymal stem cell‐derived exosomes by Xunian, Zhou, Kalluri, Raghu

“…Mesenchymal stem cells (MSC) are multipotent stromal cells with the potential to differentiate into several cell types. MSC‐based therapy has emerged as a…”
Get full text

Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity by Ogitani, Yusuke, Hagihara, Katsunobu, Oitate, Masataka, Naito, Hiroyuki, Agatsuma, Toshinori

“…Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic…”
Get full text

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor by Xie, Chengying, Wan, Xiaozhe, Quan, Haitian, Zheng, Mingyue, Fu, Li, Li, Yun, Lou, Liguang

“…Abrogating tumor angiogenesis by inhibiting vascular endothelial growth factor receptor‐2 (VEGFR2) has been established as a therapeutic strategy for treating…”
Get full text

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development by Kiyoi, Hitoshi, Kawashima, Naomi, Ishikawa, Yuichi

“…FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an important role in hematopoietic cell survival, proliferation and…”
Get full text

Artificial intelligence in oncology by Shimizu, Hideyuki, Nakayama, Keiichi I.

“…Artificial intelligence (AI) has contributed substantially to the resolution of a variety of biomedical problems, including cancer, over the past decade. Deep…”
Get full text